TATVANSETATVA CHIN PHARM CHEM LTDHighPositive
Announced Fri, 17 Jul · 15:51 IST

Q1 results, Rs 200 Cr greenfield expansion and director re-appointments

Major Capex Above 10pct NetworthCapex & Operations View source PDF

TATVA · price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reaction · full curve 14 horizons · vs prior close
+18.3%1-day move
₹1430.00
prior close
base price
After-mkt
timing
5m10m15m30m1D2D3D4D5D7D15D1M2M3M
+18.3+16.2+19.6+20.2+27.1
Up moveDown movePending
AI summary

Board approved Q1 FY27 results, greenfield capacity expansion at Dahej-III in Bharuch, and director re-appointments. Standalone revenue rose to Rs 1,467 mn from Rs 1,091 mn YoY; PAT more than doubled to Rs 104.46 mn from Rs 51.33 mn. Greenfield plan adds 344 KL reactor capacity for about Rs 200 Cr over about 21 months, funded by internal accruals and debt. Borrowing limit hiked from Rs 300 Cr to Rs 1,000 Cr, subject to shareholder approval. MD and two Whole-time Directors re-appointed for 3 years from Feb 2027.

Likely market impact

Strong Q1 with doubled profit. Rs 200 Cr greenfield capex signals growth push; higher debt limit adds leverage but supports expansion.